Ketamine, a dissociative anesthetic, has carved itself a spot in the world of mental health care over the past two decades.

Escalating concerns over impending tariffs and President Trump's foreign policies have fueled uncertainty and instability in ...

Spravato has been approved since 2019 for TRD, with its label extended the following year as a rescue therapy for adults with major depressive disorder (MDD) who were at risk of self-harm or suicide.

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Months after Massachusetts voters rejected a ballot question that would permit adults to use and grow certain psychedelic drugs, some state lawmakers have begun proposing bills to legalize psilocybin.

Spravato is the first ketamine-based medicine approved to treat depression, and also the first of a new class of glutamate NMDA receptor-targeting drugs that have ended a decades-long drought at ...

Supernus Pharmaceutical’s stock declined following the release of disappointing Phase IIb trial results for SPN-820, an ...

Trump’s “first buddy” Elon Musk made a lively, chaotic and unpredictable appearance at the Conservative Political Action ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.